Drug
Srp 5051
Srp 5051: highest development phase Phase 1/2, developed by Sarepta Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRP-5051 NCT03675126 | Phase 1/2 | Muscular Dystrophy, Duchenne |
| SRP-5051 NCT03375255 | Phase 1 | Muscular Dystrophy, Duchenne |
Latest
No recent events.
Follow Srp 5051 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.